Rapamycin binding protein

Partaledis, J. A., Fleming, M. A., Harding, M. W., and Berlin, V. (1992). Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/ rapamycin binding protein. Yeast 8, 673-680. 

The Schreiber group has fiuther carried out structural and mechanistic studies combined with chemistry and biology [128]. The solution structure of FK506 and rapamycin binding protein (FKBP) has been determined by NMR and the structure of FKBP, complexed with FK506, has also been determined by X-ray crystallography. 

Rapamycin is an immunosuppressive diug and an inhibitor of S6K1 (also known as p70S6-kinase) which phosphorylates ribosomal S6 protein. S6K1 is activated in response to insulin via activation of Akt. Rapamycin binds to a specific target protein (mTOR, mammalian target of rapamycin) which is functionally located downstream of Akt, but upstream... 

A new class of immunosuppressive agents called proliferation-signal inhibitors (PSIs) includes sirolimus (rapamycin) and its derivative everolimus. The mechanism of action of PSIs differs from that of the calcineurin inhibitors. PSIs bind the circulating immunophilin FK506-binding protein 12, resulting in an active complex that blocks the molecular target of rapamycin (mTOR). 

Many antibiotics, which inhibit protein synthesis, do not bind to ribosomes but block any of a variety of vital chemical processes needed for growth. Among them are pseudomonic acid, which inhibits isoleucyl-tRNA synthetase from many gram-positive bacteria.1111/VV Rapamycin, best known as an immunosuppressant (Box 9-F), inhibits phosphoinositide-3-kinase and also phosphorylation of the cap-binding protein 4G, a component of the eukaryotic initiation factor complex (Fig. 29-11 ).ww The bacterial enzyme peptide deformylase, which is absent from the human body, has been suggested as a target for design of synthetic antibiotics. 01... 

Sirolimus binds to the cytosolic protein FK-binding protein R (FKBP-12) but does not block calcineurin activity. It does not bind to cyclophilins, which are cytosolic receptors for cyclosporine. Unlike cyclosporine and tacrolimus, sirolimus does not inhibit the activation of NFAT responsive genes. After binding to its cytosolic receptors, sirolimus inhibits a protein kinase, the mammalian target of rapamycin (mTOR) pathway, via suppression of PP2-A. When mTOR is inhibited, the cells will not proceed to the S phase, and the cell cycle will be blocked (Fig. 4.3). As a result, sirolimus blocks T-cell proliferation but its effects are downstream of the IL-2 receptors. IL-2 binding to its receptors activates intracellular protein kinases that in turn activate gene transcription and T-cell proliferation. 

Sirolimus, a macrolide antibiotic, in one mode of action, binds to FK506-binding protein (FKBP12), inhibiting the activation of mammalian target of rapamycin (mTOR), which, in turn, blocks the cellular transition from G, to the S phase of the cell cycle (35). Sirolimus was approved by the Food and Drug Administration (FDA) in 1999 for the prevention of renal... 

Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE, FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells, Eur J Immunol I 995 25(2) 563-571. 

The crystal structure of the cyclophilin-CsA-calcineurin ternary structure has yet to be resolved but the ternary structure formed by rapamycin-mediated interactions between FKBP12 and the 12-kDa fKBP-rapamycin binding (FRB) domain of the 289-kDa FRAP protein has been determined with 2.7 A resolution (Choi et al, 1996), which has more recently been refined to 2.2 A resolution (Liang et al, 1999). The structure of this complex is shown in Fig. 6 (see color insert). Several similarities as well as differences in the overall mode of interaction can be seen relative to what is observed with the FKBP-FK506-cal-cineurin structure. As was seen with the FKBP-FK506 calcineurin ternary complex, there are no overall gross conformational changes... 

---